Benjamin G. Barwick

This paper engineers CCL27 mutants to enhance CAR T-cell efficacy against multiple myeloma by targeting CCR10, achieving results comparable to BCMA CAR-Ts.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

This study shows KDM6A regulates immune response genes in multiple myeloma by activating NLRC5 and CIITA, and its loss reduces MHC expression, which can be reversed by HDAC3 inhibitors.

The paper identifies IgL translocations in multiple myeloma as a marker of poor prognosis, often misclassified as standard risk due to co-occurrence with hyperdiploidy.